HistoSonics, Inc.

HistoSonics, Inc. wins the National Venture Capital Association 2025 Startup Innovator Award HistoSonics, Inc. is honored to be awarded the 2025 Startup Innovator winner by the NVCA. This award further validates the impact that histotripsy is making for patients, physicians and hospitals who are part of our paradigm shifting technology. Our team’s mission is an ideal fit for the NVCA award criteria which is to make measurable contributions to society, addressing areas of need, ongoing crises, or significant challenges. “HistoSonics is a shining example of the entrepreneurial ecosystem at its best,” said NVCA President and CEO Bobby Franklin. “It all started with groundbreaking research at the University of Michigan, followed by dedicated entrepreneurs and investors working together to bring that innovation to market. In collaboration with government medical and regulatory agencies, this incredible technology is now transforming tumor treatment, offering patients a way to fight the disease without the harsh side effects of traditional methods. By changing the paradigm of health care with this cutting-edge technology, HistoSonics, Inc. is making a profound impact on both science and society, and we are proud to name them our 2025 NVCA Startup Champion.” Our team is extremely thankful to the NVCA and their leadership team for this great recognition. We maintain committed to making a meaningful change for patients, physicians and health care institutions worldwide. NVCA Press Release on HistoSonic's Innovator Award here: https://lnkd.in/ePUC97kc

Histotripsy Patients Gain Coverage In Hong Kong By Leading Health Insurers HistoSonics, Inc. is proud to recognize that histotripsy patients in Hong Kong now have increased access to procedure coverage as two of Hong Kong’s leading healthcare insurers, HSBC Life and Manulife, recently announced their decision to cover histotripsy procedures for eligible patients enrolled in their select plans. We believe these coverage decisions recognize the potential value that non-invasive, non-toxic histotripsy offers to patients, providers and payors worldwide. HSBC Life, the insurance entity of global financial leader HSBC, has upgraded its Voluntary Health Insurance Flexi Plan in Hong Kong to provide 100% coverage over eligible expenses of Histotripsy treatment as Gleneagles Hospital Hong Kong announced plans to become the first private hospital to introduce Histotripsy treatment in Asia. Concurrently, Manulife, a global insurance and financial services provider, has extended its strategic partnership with The Chinese University of Hong Kong (CUHK) Medical Center to incorporate histotripsy as a treatment option under its ‘Medical Professional Support Service’ once the procedure becomes publicly available at the CHUK Medical Center. #Histotripsy #InnovationMatters #GlobalAccessToInnovation

HistoSonics, Inc. is honored to partner with Gleneagles Hospital Hong Kong for the upcoming launch of the first private hospital histotripsy program in Asia. This histotripsy program in Hong Kong was made possible by the continued leadership of Mr. Li Ka Shing and the Li Ka Shing Foundation team whose donations brought the first histotripsy systems to the The University of Hong Kong Hospital and The Chinese University of Hong Kong Hospital and now make histotripsy available at Gleneagles Hospital Hong Kong. Dr Kenneth Tsang, Chief Executive Officer of Gleneagles Hospital Hong Kong and Regional Chief Executive Officer of IHH Healthcare North Asia, said, “We are excited to be Asia’s first private hospital to offer this novel treatment to local patients with our fully trained medical team. Our shared vision of providing histotripsy to those who may benefit from a non-invasive, non-toxic method to destroying liver tumors continues to drive these clinical partnerships across the world. #PartnersInInnovation #Histotripsy #GlobalImpact

HistoSonics, Inc. is proud to announce that the Michael E. DeBakey Veterans Affairs Medical Center in Houston is the first U.S. Department of Veterans Affairs hospital to acquire the Edison Histotripsy System. Our partners, Fidelis Sustainability Distribution LLC, have led the way in bringing histotripsy to Veterans in the Houston, TX. area, demonstrating that Veterans can and should have early access to innovative health care. HistoSonics, Inc. and Fidelis Sustainability Distribution LLC have made our "Project Hero" a multi-year mission to prioritize Veterans health and to provide non-invasive histotripsy for those suffering from liver tumors. Thank you to the leadership at the Houston VA, Veterans Affairs Department, and the doctors who champion innovation for Veterans. #MeetEdison #Histotripsy #FidelisSustainabilityDistribution #VeteranPartners

HistoSonics, Inc. is proud to host James Porter, MD. and Arun Rai, MD. as part of our ongoing webinar series where they will discuss histotripsy's potential for the destruction of kidney tumors. The webinar titled, "New Frontiers for Histotripsy: Scientific Review of Clinical Experience and #HOPE4KIDNEY Trial" will be held Tuesday March 18th at 7:00 PM Eastern. Please register for this virtual event using the QR code on the invitation below or with the following link. https://lnkd.in/ebkpFg3f We look forward to an interactive session for those in attendance with a review of histotripsy's unique mechanism of action and non-invasive approach to the destruction of tumors with ample opportunity for Q&A. #histotripsy #newfrontiers #partnersininnovation

Do you have Patient Access experience and love to help patients obtain insurance coverage? You'll love the culture here! Plymouth, MN (hybrid) #patientaccess #priorauthorization #minneapolisjobs

HistoSonics, Inc. is thrilled to have had standing room only attendance at our #SIOVegas 2025 "A Year In Review" panel discussion on the first year of histotripsy's use in clinical practice. We'd like to offer a special thank you to Dr.'s Christos Georgiades MD, PhD, and Bruno Odisio MD, PhD, who shared their early experiences with histotripsy on the panel, as well as many of SIO's leaders who engaged in this interactive session. Also, we appreciate the insights and perspective shared by Brian Fuller MBA, Senior Director, Clinical Operations at Providence Mission Hospital, on what strategies supported their successful clinical histotripsy program. We look forward to continuing our growing partnerships and advancing meaningful change for patients worldwide. #PartnersInInnovation #SIOVegas #MinimallyInvasiveIsntMinimalEnough #Histotripsy

HistoSonics, Inc. is honored to attend #siovegas this week in Las Vegas and to have Christos Georgiades MD, PhD. and Bruno Odisio MD, PhD. lead an interactive "Histotripsy Year In Review" panel review during a breakfast symposium Saturday, February 1st, in the Bronze Room outside the SIO Exhibition Area from 7:15 am - 8:45 am.?? ? Histotripsy experts will deliver information on the science of histotripsy, the latest clinical information, research updates and future opportunities. Also, we welcome Brian Fuller MBA, Senior Director of Clinical Operations, from Providence Mission Hospital to describe the business experience of a successful histotripsy program. ? This breakfast event is open to all SIO clinicians and administrators and we look forward to sharing the future of IO with #siovegas leaders. ? #PartnersInInnovation #Histotripsy #TheFutureofIO

HistoSonics, Inc. is honored to attend Spectrum Miami 2025 this week, Thursday January 16th through Saturday January 18th, where we will have the latest updates in histotripsy and hands-on time with the Edison Histotripsy System for physicians and staff. Dr. Mikhail Silk from NYU Langone Medical Center will present an overview of histotripsy and his experience at the "State of the Art" session on Saturday, January 18th at 11:20 am. Follow his session with a personalized planning and treatment session at the HistoSonics booth where you can "Meet Edison". #SPECTRUM2025 #Histotripsy #MinimallyInvasiveIsntMinimalEnough